Tradestie Institutional Equity Comparison Engine

CRSP vs PTGX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PTGX Overall Edge

PTGX Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Protagonist Therapeutics, Inc (PTGX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus PTGX at 36.9x Forward P/E and 58.6% operating margin (+5723.6% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against PTGX sits in CONSOLIDATION (3rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs PTGX 36.9x Fwd P/E
Growth & Margin Winner PTGX
Op Margin -2058.6% vs 58.6% ยท YoY +1325.1% vs +5723.6%
Momentum & Technical Winner PTGX
1Y -20.5% vs +50.6% ยท 52W Pos 1% vs 58%
Options & Structure Winner PTGX
BREAKDOWN (52nd %ile IV) vs CONSOLIDATION (3rd %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
PTGX NASDAQ
Protagonist Therapeutics, Inc
Pharmaceutical Preparations
$125.40
-4.24% 1D
Market Cap $8.7B
1M Return -2.6%
1Y Return +50.65%
Forward P/E 36.9x
Unified AI Score
34.5 / 100 SELL
Tech 14.0 Fund 43.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% PTGX +50.65% Spread: +71.19 pp (PTGX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue PTGX Revenue CRSP Op. Margin PTGX Op. Margin Margin Edge
FY2018 $0M $30M -5087.8% -136.7% PTGX
FY2019 $290M $0M 16.1% -34857.6% CRSP
FY2020 $0M $30M -49295.5% -225.4% PTGX
FY2021 $910M $30M 40.8% -460.0% CRSP
FY2022 $0M $30M -56190.4% -494.2% PTGX
FY2023 $370M $60M -60.0% -156.1% CRSP
FY2024 $40M $430M -1250.4% 58.2% PTGX
FY2025 $0M $50M -18933.6% -343.6% PTGX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (3) vs PTGX (7)
Institutional Metric CRSP PTGX Criterion Row Winner
Market Capitalization Scale $4.1B $8.7B Larger Scale PTGX
Trailing P/E Ratio Valuation 23.4x 28.1x Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x 36.9x Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% +5723.6% Higher Growth PTGX
Operating Margin (TTM) Profitability -2058.6% 58.6% Higher Margin PTGX
Net Profit Margin Profitability 0.0% 62.0% Higher Margin PTGX
Return on Equity (ROE) Capital Efficiency -25.6% 39.6% Higher ROE PTGX
52-Week Range Position Momentum 1% ($40โ€“$63) 58% ($77โ€“$161) Stronger Trend PTGX
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 1.02ฮฒ ยท 35% Vol Lower Realized Risk PTGX
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 34.5 / 100 (SELL) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs PTGX Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PTGX CONSOLIDATION
64d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 3rd %ile
IV Regime Compressed (<25th %ile)
Live PTGX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor PTGX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.